{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T21:44:19Z","timestamp":1785793459126,"version":"3.56.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ijgc.2026.104813","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:20:17Z","timestamp":1781652017000},"page":"104813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["American Society of Clinical Oncology annual meeting 2026: key clinical trial updates in gynecologic oncology"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3031-7928","authenticated-orcid":false,"given":"Marina Acevedo Zarzar","family":"de Melo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2907-4605","authenticated-orcid":false,"given":"J\u00e9ssica Monteiro","family":"Vasconcellos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8194-7594","authenticated-orcid":false,"given":"Mariana Carvalho","family":"Gouveia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Let\u00edcia Vecchi","family":"Leis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7133-0009","authenticated-orcid":false,"given":"Aniceto Lopes","family":"da Silva Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Mandarano","family":"de Mattos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7713-0100","authenticated-orcid":false,"given":"Mariana","family":"Scaranti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ijgc.2026.104813_bib1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJM199503093321002","article-title":"The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer","volume":"332","author":"van der Burg","year":"1995","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104813_bib2","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"issue":"9990","key":"10.1016\/j.ijgc.2026.104813_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijgc.2026.104813_bib4","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2020.02.020","article-title":"Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III\/IV ovarian, tubal and peritoneal cancers in phase III randomised trial","volume":"130","author":"Onda","year":"2020","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104813_bib5","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)","volume":"30","author":"Fagotti","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"suppl 17","key":"10.1016\/j.ijgc.2026.104813_bib6","article-title":"TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33\/AGO-OVAR OP7)","volume":"43","author":"Mahner","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104813_bib7","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.3802\/jgo.2023.34.e82","article-title":"Optimal number of neoadjuvant chemotherapy cycles prior to interval debulking surgery in advanced epithelial ovarian cancer: a systematic review and meta-analysis of progression-free survival and overall survival","volume":"34","author":"Coada","year":"2023","journal-title":"J Gynecol Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.104813_bib8","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.2026.44.16_suppl.5505","article-title":"CHRONOlogy of surgery after neoadjuvant chemotherapy treatment for ovarian cancer: the CHRONO randomized phase II trial","volume":"44","author":"Ferron","year":"2026","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ijgc.2026.104813_bib9","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the Aurelia open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104813_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101974","article-title":"Beyond resistance: redefining the therapeutic landscape of platinum-resistant ovarian cancer","volume":"35","author":"De Oliveira","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104813_bib11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12943-024-02076-x","article-title":"Efficacy and safety of chiauranib in a combination therapy in platinum-resistant or refractory ovarian cancer: a multicenter, open-label, phase Ib and II study","volume":"23","author":"Li","year":"2024","journal-title":"Mol Cancer"},{"issue":"suppl 17","key":"10.1016\/j.ijgc.2026.104813_bib12","article-title":"A phase III CHIPRO study of chiauranib plus weekly paclitaxel for platinum-resistant or refractory ovarian cancer","volume":"44","author":"Wu","year":"2026","journal-title":"J Clin Oncol."},{"issue":"23","key":"10.1016\/j.ijgc.2026.104813_bib13","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab Soravtansine in FR\u03b1-Positive, Platinum-Resistant Ovarian Cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med."},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.104813_bib14","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1200\/JCO.2026.44.16_suppl.5506","article-title":"A randomized phase II trial of mirvetuximab soravtansine in folate receptor alpha (FR\u03b1)-high recurrent ovarian cancer eligible for platinum-based chemotherapy (MIROVA\/AGO-OVAR 2.34)","volume":"44","author":"Harter","year":"2026","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ijgc.2026.104813_bib15","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104813_bib16","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.2012.307","article-title":"Final overall survival results of phase III GCIG Calypso trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients","volume":"107","author":"Wagner","year":"2012","journal-title":"Br J Cancer"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.104813_bib17","article-title":"GLORIOSA: a randomized, open-label, phase 3 study of mirvetuximab soravtansine with bevacizumab vs. bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer","volume":"41","author":"O\u2019Malley","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10496","key":"10.1016\/j.ijgc.2026.104813_bib18","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/S0140-6736(25)01040-2","article-title":"Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial","volume":"405","author":"Olawaiye","year":"2025","journal-title":"Lancet"},{"issue":"10538","key":"10.1016\/j.ijgc.2026.104813_bib19","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(26)00462-9","article-title":"Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial","volume":"407","author":"Lorusso","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.ijgc.2026.104813_bib20","series-title":"Presented at: 2026 ASCO Annual Meeting","author":"Gilbert","year":"2026"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104813_bib21","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00428-023-03629-z","article-title":"Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors","volume":"483","author":"\u0160afanda","year":"2023","journal-title":"Virchows Arch"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104813_bib22","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1097\/PAS.0000000000001944","article-title":"PRAME expression in cancer. A systematic immunohistochemical study of >5800 epithelial and nonepithelial tumors","volume":"46","author":"Kaczorowski","year":"2022","journal-title":"Am J Surg Pathol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.104813_bib23","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1200\/JCO.2026.44.16_suppl.5509","article-title":"Phase 1a study results for IMA203CD8, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in ovarian cancer","volume":"44","author":"Busse","year":"2026","journal-title":"J Clin Oncol."},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.104813_bib24","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/JCO.2026.44.16_suppl.5513","article-title":"Results of phase 1 dose escalation of monotherapy with TUB-040, a novel NaPi2b-targeting exatecan antibody-drug conjugate, in patients with platinum-resistant ovarian cancer","volume":"44","author":"Van Gorp","year":"2026","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.ijgc.2026.104813_bib25","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1177\/1758834011422557","article-title":"c-MET as a potential therapeutic target and biomarker in cancer","volume":"3","author":"Sierra","year":"2011","journal-title":"Ther Adv Med Oncol"},{"issue":"28","key":"10.1016\/j.ijgc.2026.104813_bib26","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1038\/s41388-021-01863-w","article-title":"HGF\/c-MET pathway in cancer: from molecular characterization to clinical evidence","volume":"40","author":"Fu","year":"2021","journal-title":"Oncogene"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.104813_bib27","doi-asserted-by":"crossref","first-page":"5514","DOI":"10.1200\/JCO.2026.44.16_suppl.5514","article-title":"Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein\u2013targeting antibody-drug conjugate: results from patients with platinum-resistant ovarian\/primary peritoneal\/fallopian tube cancer (PROC)","volume":"44","author":"Fleming","year":"2026","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2026.104813_bib28","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med."},{"issue":"23","key":"10.1016\/j.ijgc.2026.104813_bib29","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104813_bib30","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","volume":"35","author":"Powell","year":"2024","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.104813_bib31","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1200\/JCO.2026.44.16_suppl.5502","article-title":"Updated overall survival analysis and examination of subsequent therapy in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin\/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG-GY018 trial","volume":"44","author":"Eskander","year":"2026","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104813_bib32","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/s41591-025-03566-1","article-title":"Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial","volume":"31","author":"Eskander","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ijgc.2026.104813_bib33","first-page":"1884","article-title":"PD-1 or PD-L1 inhibitors in addition to first-line chemotherapy for endometrial cancer: an extracted individual patient data meta-analysis","volume":"19","author":"Carvalho Gouveia","year":"2025","journal-title":"Ecancermedicalscience"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104813_bib34","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(24)00334-6","article-title":"Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Colombo","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104813_bib35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104813_bib36","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.annonc.2024.04.007","article-title":"MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy","volume":"35","author":"Pignata","year":"2024","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.104813_bib37","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2026.44.16_suppl.5501","article-title":"Long-term survival rates and cure modeling with dostarlimab plus chemotherapy in mismatch repair deficient\/microsatellite instability-high (dMMR\/MSI-H) primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO\/GOG-3031\/RUBY trial","volume":"44","author":"Powell","year":"2026","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104813_bib38","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104813_bib39","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1136\/ijgc-2024-006091","article-title":"The rise of antibody-drug conjugates in advanced endometrial cancer","volume":"34","author":"Gouveia","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104813_bib40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab Deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.ijgc.2026.104813_bib41","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1200\/JCO.23.02767","article-title":"Efficacy and safety of Sacituzumab Govitecan in patients with advanced solid tumors (TROPiCS-03): analysis in patients with advanced endometrial cancer","volume":"42","author":"Santin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.104813_bib42","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1200\/JCO.2026.44.16_suppl.5512","article-title":"Safety and efficacy of BAT8006 in combination with BAT1308 in patients with advanced endometrial cancer","volume":"44","author":"Long","year":"2026","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104813_bib43","first-page":"322","article-title":"Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022","volume":"5","author":"Wu","year":"2025","journal-title":"J Natl Cancer Cent"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104813_bib44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N Engl J Med"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.104813_bib45","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1200\/JCO.2026.44.16_suppl.5508","article-title":"A phase 1\/2 study of the next-generation nectin-4\u2013targeting antibody-drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic cervical cancer","volume":"44","author":"Ciuleanu","year":"2026","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104813_bib46","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000522206","article-title":"Trophoblast cell surface antigen 2 expression in human tumors: a tissue microarray study on 18,563 tumors","volume":"89","author":"Dum","year":"2022","journal-title":"Pathobiology"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.104813_bib47","first-page":"5507","article-title":"Updated efficacy results from the phase I cervical cancer cohort of BAT8008, a TROP-2\u2013directed antibody-drug conjugate, in patients with advanced cervical cancer","volume":"44","author":"Song","year":"2026","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104813_bib48","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ygyno.2017.03.006","article-title":"Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors","volume":"145","author":"Bregar","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.104813_bib49","first-page":"5515","article-title":"Updated safety and efficacy of puxitatug samrotecan (Puxi-Sam, AZD8205) in patients with endometrial cancer or ovarian cancer: phase I\/IIa BLUESTAR study","volume":"44","author":"Gaillard","year":"2026","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.104813_bib50","article-title":"Puxitatug samrotecan (AZD8205) vs chemotherapy in patients with B7-H4\u2013selected advanced\/metastatic endometrial cancer: the phase III randomized Bluestar-Endometrial01 (BE01)\/GOG-3110\/ENGOT-en28 trial","volume":"44","author":"Slomovitz","year":"2026","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26003440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26003440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:47:01Z","timestamp":1785790021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26003440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1048891X26003440"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104813","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"American Society of Clinical Oncology annual meeting 2026: key clinical trial updates in gynecologic oncology","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104813","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104813"}}